Prior myeloma treatment history
| Characteristic . | N = 120 . |
|---|---|
| Years since diagnosis, median (range) | 4.6 (0.8-21.2) |
| Prior lines of therapy, median (range) | 5 (3-15) |
| Prior therapy, n (%) | |
| Lenalidomide | 120 (100) |
| Relapsed | 19 (16) |
| Refractory | 101 (84) |
| Lenalidomide as last therapy prior to ClaPD* | 36 (30) |
| Treatment† | 26 (22) |
| Maintenance‡ | 10 (8) |
| Bortezomib | 119 (99) |
| Relapsed | 25 (22) |
| Refractory | 94 (78) |
| Double refractory | 81 (68) |
| Autologous stem cell transplant | 89 (74) |
| Thalidomide | 74 (62) |
| Cyclophosphamide | 72 (60) |
| Doxorubicin | 53 (43) |
| Carfilzomib | 31 (25) |
| Cisplatin | 26 (22) |
| Bendamustine | 21 (18) |
| Characteristic . | N = 120 . |
|---|---|
| Years since diagnosis, median (range) | 4.6 (0.8-21.2) |
| Prior lines of therapy, median (range) | 5 (3-15) |
| Prior therapy, n (%) | |
| Lenalidomide | 120 (100) |
| Relapsed | 19 (16) |
| Refractory | 101 (84) |
| Lenalidomide as last therapy prior to ClaPD* | 36 (30) |
| Treatment† | 26 (22) |
| Maintenance‡ | 10 (8) |
| Bortezomib | 119 (99) |
| Relapsed | 25 (22) |
| Refractory | 94 (78) |
| Double refractory | 81 (68) |
| Autologous stem cell transplant | 89 (74) |
| Thalidomide | 74 (62) |
| Cyclophosphamide | 72 (60) |
| Doxorubicin | 53 (43) |
| Carfilzomib | 31 (25) |
| Cisplatin | 26 (22) |
| Bendamustine | 21 (18) |
Patients who received lenalidomide as part of last line of therapy prior to start of ClaPD.
Treatment dosing: lenalidomide in combination with corticosteroid at 25 mg per day or renal-adjusted dose.
Maintenance lenalidomide: lenalidomide monotherapy after achievement of maximum response on prior regimen, dosing not exceeding 10 mg per day.